Dual-protease inhibitor (PI) therapy was associated with an increased rate of virological failure

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1625, 2008-01, pp. : 8-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dual protease inhibitor (PI) therapy and the inclusion of ritonavir do not appear to increase the incidence of hepatotoxicity

By  

Inpharma, Vol. 1, Iss. 1340, 2002-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

Dual protease inhibitor therapy in the management of the HIV-1

By Yu K.   Daar E.S.  

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 7, 2000-12 ,pp. : 1331-1342

Informa Healthcare

Access to resources Recommend Favorite

Metabolic Complications Associated with HIV Protease Inhibitor Therapy

By Nolan D.  

Drugs, Vol. 63, Iss. 23, 2003-01 ,pp. : 2555-2574

Adis International

Access to resources Recommend Favorite

Protease inhibitor (PI)-containing HAART is associated with a reduced bone mineral density

By  

Reactions Weekly, Vol. 1, Iss. 1185, 2008-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Protease inhibitor (PI)-containing HAART is associated with a reduced bone mineral density

By  

Inpharma, Vol. 1, Iss. 1621, 2008-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite